FDA Determines Regulatory Review Period for ZILVER PTX Drug Eluting Peripheral Stent

Summary

The US Food and Drug Administration (FDA) has officially set a review period for Boston Scientific Scimed, Inc.'s patent extension request for the ZILVER PTX drug eluting peripheral stent, as mandated by law.